Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.46 USD
Change Today +0.90 / 13.72%
Volume 1.6M
PGNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 7:40 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Key Developments

Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR®

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced that Valeant submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. RELISTOR is a peripherally acting mu-opioid receptor antagonist specifically designed to block the constipating effects of opioid pain medications in the gastrointestinal tract. RELISTOR does not cross the blood-brain barrier, therefore relieving the distressing effects of the constipation without affecting the analgesic effect of the opioid. RELISTOR Subcutaneous Injection has been FDA approved since 2008 to treat OIC in patients with advanced illness who are receiving palliative care, and was approved in 2014 for the treatment of OIC in patients with chronic non-cancer pain.

Progenics Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 11:00 AM

Progenics Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 11:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Mark R. Baker, Chief Executive Officer, Director and Member of Science & Strategy Committee.

Progenics Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Progenics Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $248,000 against $1,815,000 for the same period a year ago, reflecting RELISTOR royalty income of $0.1 million compared to $0.7 million in the 2014 period, based on net sales reported to the company by its commercialization partner, Valeant Pharmaceuticals International, Inc. The decrease in royalty revenue reflects a short-term wholesaler inventory reduction initiative implemented in the fourth quarter of 2014 by Salix Pharmaceuticals, Inc., which was subsequently acquired by Valeant. In addition, collaboration revenue declined to $0.1 million from $1.0 million in the 2014 period, primarily due to a milestone from Fuji recognized in the first quarter of 2014. Operating loss was $10,266,000 against $9,325,000 for the same period a year ago. Net loss was $10,254,000 or $0.15 per basic and diluted share against $9,313,000 or $0.15 per basic and diluted share for the same period a year ago.

Progenics Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 06, 2015

Progenics Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 06, 2015

Progenics Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2015

Progenics Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2015., at 10:00 US Eastern Standard Time. Location: The Landmark at Eastview, Rockland Room. Agenda: To consider electing seven directors to serve until the next Annual Meeting of Stockholders and until their successors are elected and have qualified; to approve on an advisory basis, the compensation of the company's named executive officers; and to ratify the Board's selection of Ernst & Young LLP to serve as the Company's independent registered public accounting firm for 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $7.46 USD +0.90

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $20.33 USD +3.07
CTI BioPharma Corp $1.95 USD +0.02
Genocea Biosciences Inc $13.73 USD +0.78
Inovio Pharmaceuticals Inc $8.16 USD +0.17
Peregrine Pharmaceuticals Inc $1.31 USD +0.01
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings 100.0x
Price/Sales 10.7x
Price/Book 4.0x
Price/Cash Flow 114.2x
TEV/Sales 8.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.